ClinicalTrials.gg
RecruitingNCT06456255Updated May 15, 2025

Bupivacaine and Epinephrine Injection Study

A Phase 2/3 interventional study of Sensorcaine with Epinephrine and Sham injection in Sinus Disease, Anesthesia and Bleeding, sponsored by Amin Javer. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Amin Javer · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

Endoscopic sinus surgery (ESS) is a common otolaryngologic procedure that aims to remove the partitions that separate the sinus cavities, remove inflamed tissue, and optimize the sinuses for topical medication use. In this procedure, the surgeon will inject a combination of drugs, local anesthetics, and vasoconstrictors, to reduce bleeding and improve visualization. However, previous studies have shown similar results when injected with only saline. In this study, investigators want to determine if the injection of local anesthesic+vasoconstrictor compared to no injection at all makes any difference in improving the surgeon's visualization during an ESS.

02

Conditions studied

  • Sinus Disease
  • Anesthesia
  • Bleeding

Keywords

  • endoscopic sinus surgery
  • bupivacaine
  • epinephrine
03

In context

Paranasal Sinus Diseases

24 studies on the registry are indexed under Paranasal Sinus Diseases; 7 are open to participants now.

This study's planned enrollment of 80 is close to the median of 80 across 16 interventional studies indexed under Paranasal Sinus Diseases.

Browse Paranasal Sinus Diseases studies →

Lead sponsor

Amin Javer is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 years or older
  • Scheduled for primary ESS (including septoplasty)

Exclusion criteria

Exclusion Criteria:

  • Cystic fibrosis
  • Systemic vasculitis or any bleeding disorders
  • Known or suspected to bupivacaine or epinephrine
  • Previous sinus surgery
  • Inhaled drug use (i.e., cocaine) in the preceding 6 months
  • Nasal tumors
  • Patients on antiarrhythmics.
  • Patients with history of severe liver illness.
  • Patients identified as high-risk for complications during preoperative assessment with the anesthesiologist (e.g. untreated hypertension, ischemic heart disease, cerebral vascular insufficiency, heart block, peripheral vascular disorder, uncontrolled hyperthyroidism and diabetes)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Injection

    - Injection 0.25% bupivacaine with 1:200,000 epinephrine

    Drug: Sensorcaine with Epinephrine

  • Placebo comparator
    Sham injection

    - Sham injection (only puncture, no injecting anything)

    Other: Sham injection

Interventions

  • DrugSensorcaine with Epinephrine

    Drug pages: BupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EpinephrineStudies of EpinephrineEpinephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The combination contains 0.25% bupivacaine hydrochloride (2.5 mg/mL) and epinephrine bitartrate \[(1:200,000) 5 mcg/mL\] per vial.

  • OtherSham injection

    Punctures without any medication injected onto the septum

06

What researchers measure

Primary outcomes

  1. Boezzart bleeding score

    Change in mean surgical field quality as determined by the Boezzart bleeding score. Boezaart score of 0 indicates no bleeding, whereas the maximum score of 5 indicates severe bleeding (constant suctioning required).

    Time frame: throughout study completion, one day study visit

Secondary outcomes

  1. Total blood loss

    Change in total blood between injection and sham group measured in millilitres

    Time frame: throughout study completion, one day study visit

  2. Surgical time

    Change in surgical time between injection and sham group measure in minutes

    Time frame: throughout study completion, one day study visit

  3. Mean arterial pressure (MAP)

    Change in Mean arterial pressure (MAP) between injection and sham group measured in millimeters of mercury (mm Hg)

    Time frame: throughout study completion, one day study visit

  4. Postoperative bleeding

    Change in postoperative bleeding between injection and sham group measured in mililiters

    Time frame: throughout study completion, one day study visit

  5. Postoperative pain

    Change in postoperative pain between injection and sham group measured with a Visual Analog Scale (VAS) grading from 0 (no pain) to 5 (severe pain)

    Time frame: throughout study completion, one day study visit

07

Study locations

1 of 1 sites recruiting
  • St.Paul's Hospital Sinus Center
    Vancouver, British Columbia V6Z 1Y6, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for May 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2024
First posted
Jun 13, 2024
StartActual
Nov 15, 2024
Primary completionEst.
May 2025
CompletionEst.
Jul 2025
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06456255
Lead sponsor
Amin Javer
Responsible party
Amin Javer (Clinical Professor, St. Paul's Hospital, Canada) — Sponsor-investigator
First posted
Jun 13, 2024
Start date
Nov 15, 2024
Primary completion
May 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
May 15, 2025

Study contacts

Amin Javer
Contact
sinusdoc@me.com
6048069926

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Epinephrine

Start the discussion